COVID-19: Drug Targets and Potential Treatments
Carmen Gil(Instituto de Salud Carlos III), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Covadonga Alonso(Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria), Vanesa Nozal(Centro de Investigaciones Biológicas Margarita Salas), Tiziana Ginex(Universitat de Barcelona), Miguel Ángel Cuesta-Geijo(Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria), Inés Maestro(Centro de Investigaciones Biológicas Margarita Salas), Nuria E. Campillo(Centro de Investigaciones Biológicas Margarita Salas), Jesús Urquiza(Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria), Lucía Barrado-Gil(Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria)
Cited by 469
Related Papers
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
|Autophagy|2016|6k
ICTV Virus Taxonomy Profile: Asfarviridae
|Journal of General Virology|2018|492
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334